This company has been marked as potentially delisted and may not be actively trading. Oncobiologics (ONS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ONS vs. PLX, IKT, IZTC, JATT, CRTX, ZIVO, ALVR, FNCH, SRNE, and SQZShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), Finch Therapeutics Group (FNCH), Sorrento Therapeutics (SRNE), and SQZ Biotechnologies (SQZ). These companies are all part of the "medical" sector. Oncobiologics vs. Its Competitors Protalix BioTherapeutics Inhibikase Therapeutics Invizyne Technologies JATT Acquisition Cortexyme ZIVO Bioscience AlloVir Finch Therapeutics Group Sorrento Therapeutics SQZ Biotechnologies Oncobiologics (NASDAQ:ONS) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Do institutionals & insiders hold more shares of ONS or PLX? 7.2% of Oncobiologics shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 11.5% of Oncobiologics shares are owned by company insiders. Comparatively, 6.5% of Protalix BioTherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more volatility & risk, ONS or PLX? Oncobiologics has a beta of -0.27, meaning that its share price is 127% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of -0.13, meaning that its share price is 113% less volatile than the S&P 500. Is ONS or PLX more profitable? Protalix BioTherapeutics has a net margin of -21.03% compared to Oncobiologics' net margin of -464.47%. Oncobiologics' return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oncobiologics-464.47% N/A -93.28% Protalix BioTherapeutics -21.03%-30.89%-11.74% Does the media favor ONS or PLX? In the previous week, Oncobiologics' average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score. Company Overall Sentiment Oncobiologics Neutral Protalix BioTherapeutics Neutral Do analysts recommend ONS or PLX? Protalix BioTherapeutics has a consensus price target of $15.00, suggesting a potential upside of 512.24%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Oncobiologics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncobiologics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, ONS or PLX? Protalix BioTherapeutics has higher revenue and earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncobiologics$3.81M22.74-$38.84MN/AN/AProtalix BioTherapeutics$61.95M3.15$8.31M$0.0735.00 SummaryProtalix BioTherapeutics beats Oncobiologics on 9 of the 12 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONS vs. The Competition Export to ExcelMetricOncobiologicsBiological Products, Except Diagnostic IndustryMedical SectorNASDAQ ExchangeMarket Cap$86.64M$351.59M$6.04B$10.44BDividend YieldN/AN/A5.73%4.79%P/E RatioN/AN/A85.3127.07Price / Sales22.74489.32588.57190.17Price / CashN/A22.4425.7330.17Price / Book-0.883.8012.666.69Net Income-$38.84M-$133.30M$3.31B$276.03M Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONSOncobiologicsN/A$1.20-2.4%N/A-76.7%$86.64M$3.81M0.00N/AHigh Trading VolumePLXProtalix BioTherapeutics1.8901 of 5 stars$2.40+1.5%$15.00+526.3%+118.5%$190.96M$61.95M-18.42200Gap UpIKTInhibikase Therapeutics1.2629 of 5 stars$1.61-0.3%$6.50+305.0%+9.5%$121.09MN/A-0.616Gap UpIZTCInvizyne TechnologiesN/A$12.95-4.1%N/AN/A$80.96MN/A0.0029JATTJATT AcquisitionN/A$4.15-8.0%N/A+2.2%$71.59MN/A0.003Gap DownHigh Trading VolumeCRTXCortexymeN/A$1.87-8.3%N/A+169.5%$56.38MN/A-0.6355Gap UpZIVOZIVO Bioscience0.1075 of 5 stars$13.20+1.5%N/A-34.9%$50.85M$15.85K-2.7010Gap UpALVRAlloVirN/A$4.45-3.8%N/A-77.0%$22.44MN/A-0.22110News CoverageHigh Trading VolumeFNCHFinch Therapeutics Group0.6952 of 5 stars$11.52-5.2%N/A+0.2%$18.50MN/A-1.31190High Trading VolumeSRNESorrento Therapeutics0.8704 of 5 stars$0.01-9.1%N/A+71.4%$2.76M$60.32M0.00800Gap DownHigh Trading VolumeSQZSQZ BiotechnologiesN/A$0.03+10.9%N/A+10.9%$752K$18.16M-0.011,620Gap Up Related Companies and Tools Related Companies PLX Alternatives IKT Alternatives IZTC Alternatives JATT Alternatives CRTX Alternatives ZIVO Alternatives ALVR Alternatives FNCH Alternatives SRNE Alternatives SQZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ONS) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
